Stephanie Callaway
Adult Health · Fort Worth, TXNPI 1730616921
Payments from drug & device makers
Across 349 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$985
- AbbVie$763
- Lilly USA, LLC$681
- GSK$526
- AstraZeneca$505
- Boehringer Ingelheim$359
- plus $2K from 35 others
What the payments were for
- Food & beverage$6,16998%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 56 | $985 |
| AbbVie | 51 | $763 |
| Lilly USA, LLC | 42 | $681 |
| GSK | 25 | $526 |
| AstraZeneca | 25 | $505 |
| Boehringer Ingelheim | 19 | $359 |
| Pfizer | 19 | $324 |
| Astellas Pharma US Inc | 9 | $251 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $237 |
| Dexcom, Inc. | 11 | $202 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $197 |
| Abbott | 8 | $167 |
| Sanofi-aventis U.S. LLC | 8 | $142 |
| Merck | 7 | $117 |
| Corcept Therapeutics | 2 | $69 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $69 |
| Cipher Pharmaceuticals US LLC | 1 | $66 |
| Amgen | 3 | $61 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Novartis | 2 | $37 |
| Jazz Pharmaceuticals Inc. | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Si-bone, Inc. | 2 | $35 |
| Bayer | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Antares Pharma, Inc. | 2 | $26 |
| Eisai Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Bausch Health US, LLC | 1 | $19 |
| Mycovia Pharmaceuticals, Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $17 |
| Halozyme Inc | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| IBSA Pharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$113
How this compares
$6,269 in reported general payments places this provider in the 90th percentile of 933 adult health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 74 | $91,925 |
| JardianceEmpagliflozin | 78 | $55,614 |
| MounjaroTirzepatide | 43 | $53,787 |
| EliquisApixaban | 45 | $42,577 |
| LinzessLinaclotide | 17 | $20,367 |
| FarxigaDapagliflozin Propanediol | 22 | $19,767 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $14,120 |
| XareltoRivaroxaban | 16 | $13,103 |
| GlyxambiEmpagliflozin/Linagliptin | 11 | $7,652 |
| DexilantDexlansoprazole | 12 | $3,849 |
| Rosuvastatin Calcium | 274 | $3,284 |
| Gabapentin | 201 | $3,029 |
| Famotidine | 180 | $2,691 |
| Bupropion XlBupropion Hcl | 120 | $2,595 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 73 | $1,986 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $985 | $91,92574 claims |
| Boehringer IngelheimJardiance, Glyxambi | $359 | $63,26689 claims |
| Lilly USA, LLCMounjaro | $681 | $53,78743 claims |
| PfizerEliquis | $324 | $42,57745 claims |
| AbbVieLinzess, Synthroid | $763 | $21,53433 claims |
| AstraZenecaFarxiga | $505 | $19,76722 claims |
| GSKTrelegy Ellipta | $526 | $14,12011 claims |
| Johnson & JohnsonXarelto | $20 | $13,10316 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $237 | $3,84912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 933 adult health providers in Texas.
Other adult health in Fort Worth
- Lori MuhrFort Worth$16K
- Nancy SmithFort Worth$10K
- Misty SheddAllen$863K
- Melodie YoungDallas$700K
- Cynthia BedellPlano$168K
- Elizabeth Wedberg SivamAustin$71K
- Mary SalazarSan Antonio$68K
- Eric KlappholzDallas$44K
- Christin TouchetKingwood$43K
- Yulia LyuboslavskyAustin$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.